Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zoledronic acid for prevention of osteoporosis after renal transplantation
IRCT20181202041821N1Phase 3Completed
- Sponsor
- Shiraz University of Medical Sciences
- Start
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in osteoporosis comparing Zoledronic acid with Placebo saline control (2 arms). Primary endpoints: Trabecular bone score of the lumbar spine and Bone mineral density. Started Dec 2018; status: completed.
02
Drugs
zoledronic acid
03
Conditions
osteoporosis
Beyond the preview
Go deeper on IRCT20181202041821N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20181202041821N1.